Journal of Oncology Research and Therapy (ISSN: 2574-710X)

research article

Impact of Metabolic Syndrome on Prostate Cancer Diagnosis and Grade in Chinese Patients Undergoing Prostate Biopsy

Qian Zhang1, Xingbin Wu2, Binyuan Yan3, Qiji Li4, Shubin Peng5, Shaoxu Wu6, Jun Li3*

1Department of Rehabilitation Medicine, Seventh Affiliated Hospital, Sun Yat-sen University Shenzhen, People’s Republic of China

1Department of Rehabilitation Medicine, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, People’s Republic of China

2Xiacun Community Health Service Center, Shenzhen Hospital, University of Chinese Academy of Sciences, Shenzhen, People’s Republic of China

3Department of Urology, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People’s Republic of China

4Department of Orthopedic, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People’s Republic of China

5Department of Urology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

6Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

3Department of Urology, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People’s Republic of China

*Corresponding author: Jun Li, Department of Urology, Seventh Affiliated Hospital, Sun Yat-sen University, 628 Zhenyuan Road, Shenzhen, 518107, People’s Republic of China. Tel: +86-15017555405. Email: lijunsysu@163.com

Received Date: 17 December, 2018; Accepted Date: 02 January, 2019; Published Date: 10 January, 2019

1.                   Abstract

1.1.              Objective: Biologic rationale exists for the association between Metabolic Syndrome (MS) and prostate cancer. However, epidemiologic studies have been conflicting. This study aimed to evaluate the association between MS and prostate cancer diagnosis and grade in Chinese patients undergoing prostate biopsy.

1.2.              Methods: An observational study was conducted of 890 men who underwent prostate biopsy from two Chinese clinical centers. MS was defined according to the Adult Treatment Panel Ⅲ criteria. Clinicopathological factors including age, PSA, DRE, prostate volume, Body Mass Index (BMI), waist circumference, blood pressure, fasting blood sugar level, lipid profiles, and MS were considered for analysis.

1.3.              Results: 890 patients were enrolled with a median age and PSA of 67.5 years and 14.44 ng/ml respectively. 247 patients (27.75%) had MS and 404 patients (45.39%) were diagnosed with prostate cancer. Age, PSA, prostate volume, DRE, BMI and MS were significant predictors for prostate cancer detection. Out of 404 patients with prostate cancer, 200 (49.5%) had Gleason score≥4+3, which include 79(39.5%) had MS. PSA, BMI, and MS were significantly associated with an increased risk of high-grade prostate cancer.

1.4.              Conclusion: Presence of MS was associated with a significantly increased risk of diagnosis of overall and high-grade prostate cancer. However, these results need to be evaluated in large-scale prospective cohorts.

2.                   Keywords: Gleason Score; Prostate Cancer; Metabolic Syndrome; Prostate Biopsy


Page Views: 11165734